By Fineline Cube China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another indication approval filing for its avatrombopag has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is chronic immune thrombocytopenia (ITP).
Drug Profile and Development
Avatrombopag is a thrombopoietin (TPO) receptor agonist in-licensed for mainland China and Hong Kong development under a partnership between Fosun and AkaRx signed in March 2018. The drug obtained its first market nod from the NMPA in May 2020 for use in chronic liver disease-related thrombocytopenia. It generated RMB 426 million (USD 61 million) in sales in 2021 in China, where no similar product is approved for marketing.
Future Prospects and Strategic Implications
The acceptance of the filing for chronic ITP indication marks a significant milestone for Fosun Pharma in expanding the therapeutic applications of avatrombopag. By addressing the unmet medical needs in chronic ITP, Fosun aims to further solidify its position in the hematology market and contribute to improving patient outcomes. This strategic move underscores Fosun’s commitment to innovation and addressing significant medical needs through its robust pipeline of therapies.-Fineline Info & Tech